Aprea Therapeutics APRE 深 滬
已收盤 05-08 16:00:00 美东时间
0.9799
+0.099
+11.26%
華盛通- 最 高1.06
- 今 開0.93
- 成交量 97.46万股
- 最 低 0.9027
- 昨 收 0.8807
- 總市值 1213.39万
- 52周最高 2.22
- 市盈率 靜 --
- 換手率 7.87%
- 52周最低 0.548
- 委 比 59.65%
- 總股本 1238.28万
- 歷史最高 1062.20
- 量 比 6.29
- 振 幅 17.86%
- 歷史最低 0.548
- 每 手 1
- 風險率 0.41%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | 绩后暴跌10%，ARM仍获高盛、富国银行等多家大行上调目标价；康宁、优步、飞塔信息、西维斯、Agilon Health等获多家大行上调目标价
今日重点评级关注：Citizens：维持BioCryst制药"跑赢大市"评级，目标价从25美元升至28美元；富国银行：维持曼恩凯德生物医疗"超配"评级，目标价从8美元升至10美元
05-08 12:05
Oppenheimer Initiates Coverage On Aprea Therapeutics with Outperform Rating, Announces Price Target of $5
Oppenheimer analyst Matthew Biegler initiates coverage on Aprea Therapeutics (NASDAQ:APRE) with a Outperform rating and announces Price Target of $5.
05-07 18:49
Aprea Therapeutics announces annual shareholder meeting via webcast
Aprea Therapeutics announces annual shareholder meeting via webcast Aprea Therapeutics will hold its 2026 annual meeting of stockholders virtually on June 16, 2026. Shareholders will vote on election of three Class I directors to three-year terms expiring in 2029. Ballot includes ratification of Eis
04-20 18:31
10 Health Care Stocks Moving In Friday's Intraday Session
Gainers Psyence Biomedical (NASDAQ:PBM) shares increased by 40.5% to $8.25 dur...
04-18 01:05
Aprea Therapeutics Raises $30M to Advance Oncology Pipeline
The latest announcement is out from Aprea Therapeutics ( ($APRE) ). Aprea Thera...
04-02 00:14
美股大行评级 | 存储分歧大！花旗大砍17%将美光目标价从510降至425美元；Bernstein上调希捷科技目标价从500升至620美元
今日重点评级关注：Maxim Group：上调Theriva Biologics评级至"买入"，目标价1美元；HC Wainwright & Co.：维持Bicara Therapeutics"买入"评级，目标价从40美元升至42美元
04-01 16:34
Aprea Therapeutics Commences ~$30M Offering Of Warrants, Pre-Funded Warrants
Aprea Therapeutics, Inc. (Nasdaq: APRE) ("Aprea", or the "Company"), a clinical-stage precision medicine oncology company focused on the discovery and development of targeted therapies for patients with biomarker-defined
03-30 20:15
Aprea Therapeutics Announces Oversubscribed $30 Million Private Placement
Aprea Therapeutics announced a $30 million private placement financing led by Soleus Capital, with participation from other investors. The funds will support research and development, including expanding clinical trials for treatments targeting biomarker-defined cancers. The company plans to enroll patients with uterine serous carcinoma and ovarian cancer to assess its lead compound, APR-1051. The offering is expected to extend Aprea's cash runwa...
03-30 12:01
Aprea Therapeutics Highlights Positive Emerging Clinical Activity for WEE1 Inhibitor, APR-1051, with a Confirmed Partial Response in the Ongoing Phase 1 ACESOT-1051 Trial
Aprea Therapeutics announced positive clinical data for APR-1051, a WEE1 kinase inhibitor, showing confirmed partial responses in patients with biomarker-defined cancers, supporting its potential as a best-in-class therapy with a favorable safety profile and further updates expected in Q2 2026.
03-30 12:00
Aprea Therapeutics Q4 EPS $(0.32) Misses $(0.30) Estimate, Sales $3.337K Down From $205.817K YoY
Aprea Therapeutics (NASDAQ:APRE) reported quarterly losses of $(0.32) per share which missed the analyst consensus estimate of $(0.30) by 5.61 percent. This is a 34.69 percent increase over losses of $(0.49) per share
03-16 20:11
